Global histone acetylation levels: Prognostic relevance in patients with renal cell carcinoma

Cancer Science

Volumn 101, Issue 12, 2010, Pages 2664-2669

  Mosashvilli, Davit ^a,b   Kahl, Philip ^a   Mertens, Claudia ^a   Holzapfel, Stefanie ^a   Rogenhofer, Sebastian ^a   Hauser, Stefan ^a   Büttner, Reinhard ^a   Von Ruecker, Alexander ^a   Müller, Stefan C ^a   Ellinger, Jörg ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Department of Urology   (Georgia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE H4; LYSINE;

ACETYLATION; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DEACETYLATION; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONCOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

ACETYLATION; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; EPIGENESIS, GENETIC; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TISSUE ARRAY ANALYSIS;

EID: 78449274443     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01717.x     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Aben KK, Luth TK, Janssen-Heijnen ML, Mulders PF, Kiemeney LA, Van Spronsen DJ. No improvement in renal cell carcinoma survival: a population-based study in the Netherlands. Eur J Cancer 2008; 44: 1701-9.
3. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23: 2763-71.
4. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
5. Choi JK, Howe LJ. Histone acetylation: truth of consequences? Biochem Cell Biol 2009; 87: 139-50.
6. Orr JA, Hamilton PW. Histone acetylation and chromatin pattern in cancer. A review. Anal Quant Cytol Histol 2007; 29: 17-31.
7. Fritzsche FR, Weichert W, Roske A et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 2008; 8: 381.
8. Jones J, Juengel E, Mickuckyte A et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 2008; 13: 2376-85.
9. Seligson DB, Horvath S, Shi T et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-6.
10. Elsheikh SE, Green AR, Rakha EA et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009; 69: 3802-9.
11. Barlesi F, Giaccone G, Gallegos-Ruiz MI et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007; 25: 4358-64.
12. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 2008; 180: 1131-6.
13. Minardi D, Lucarini G, Filosa A et al. Prognostic role of global DNA methylation and histone acetylation in pT1a clear cell renal cell carcinoma in partial nephrectomy specimens. J Cell Mol Med 2008; 13: 2115-21.
14. Seligson DB, Horvath S, McBrian MA et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009; 174: 1619-28.
15. Ellinger J, Kahl P, Mertens C et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer 2010; [doi: ].
16. Ellinger J, Kahl P, Von Der Gathen J et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010; 70: 61-9.
17. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987; 8: 138-40. (In German.)
18. Xia X, Lemieux ME, Li W et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A 2009; 106: 4260-5.
19. Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw 2009; 7: 659-65.
20. Mahalingam D, Medina EC, Esquivel JA et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 2010; 16: 141-53.
21. Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
22. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300: 455.
23. Thrash-Bingham CA, Salazar H, Freed JJ, Greenberg RE, Tartof KD. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 1995; 55: 6189-95.
24. Uchida T, Wada C, Wang C, Egawa S, Ohtani H, Koshiba K. Genomic instability of microsatellite repeats and mutations of H-, K-, and N-ras, and p53 genes in renal cell carcinoma. Cancer Res 1994; 54: 3682-5.